Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Reindel, J. F.
Right arrow Articles by Mcguire, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reindel, J. F.
Right arrow Articles by Mcguire, E. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal Article

Toxicologic Effects of a Novel Acyl-CoA: Cholesterol Acyltransferase Inhibitor in Cynomolgus Monkeys

James F. Reindel

Department of Pathology and Experimental Toxicology Division of Warner-Lambert Company

Mark A. Dominick

Department of Pathology and Experimental Toxicology Division of Warner-Lambert Company

Thomas M.A. Bocan

Pharmacology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105

Alexander W. Gough

Department of Pathology and Experimental Toxicology Division of Warner-Lambert Company

Edward J. Mcguire

Department of Pathology and Experimental Toxicology Division of Warner-Lambert Company

PD 132301-2, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, was administered orally to cynomolgus monkeys for 2 wk at doses of 25, 50, 100, and 200 mg/kg to assess potential subacute toxicity. Sporadic episodes of soft feces and diarrhea increased in incidence from 100 to 200 mg/kg. Histopathologic alterations in adrenocortical cells of treated monkeys consisted of a dose-related decrease in cytoplasmic fine vacuolation and an increase in cytoplasmic eosinophilia most conspicuous in the zona fasciculata and reticularis. At 50, 100, and 200 mg/kg, a narrow discontinuous zone of cytotoxic cortical cell degeneration occurred in the outer zona fasciculata. Decreased fine vacuolation of cortical cells correlated ultrastructurally with reduced size and number of intracellular lipid vacuoles and biochemically with a dose-related decrease in adrenal total cholesterol (from 56 to 13% of control) and cholesteryl ester (from 51 to 3% of control) concentrations. Other ultrastructural changes noted in zona fasciculata cortical cells at all doses were an apparent increase in both smooth endoplasmic reticulum and variably sized autophagic vacuoles. Ovarian corpora lutea in some females at all doses had increased coarse vacuolation of luteal cells, foci of cellular degeneration, increased numbers of cholesterol clefts, and slight infiltrates of mononuclear cells. Sebaceous glands were atrophic in all treated monkeys due largely to a reduction in size and number of differentiated foam cells. Sebaceous gland reserve cells were hypertrophic and hyperplastic. Toxicity data from this study indicated that PD 132301-2 at 25-200 mg/kg targeted cholesterol-rich cells of the adrenals, ovaries, and skin adnexa.

Key Words: Atherosclerosis • lipid-regulating drug • adrenal • zona fasciculata • cholesteryl ester • ovary • corpus luteum • sebaceous gland

Toxicologic Pathology, Vol. 22, No. 5, 510-518 (1994)
DOI: 10.1177/019262339402200505
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. Kotsuma, T. Tokui, S. Freudenthaler, and K. Nishimura
Effects of Ketoconazole and Quinidine on Pharmacokinetics of Pactimibe and Its Plasma Metabolite, R-125528, in Humans
Drug Metab. Dispos., August 1, 2008; 36(8): 1505 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Kotsuma, T. Tokui, T. Ishizuka-Ozeki, T. Honda, H. Iwabuchi, T. Murai, T. Ikeda, and H. Saji
CYP2D6-Mediated Metabolism of a Novel Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor, Pactimibe, and Its Unique Plasma Metabolite, R-125528
Drug Metab. Dispos., March 1, 2008; 36(3): 529 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Namatame, H. Tomoda, S. Ishibashi, and S. Omura
Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages
PNAS, January 20, 2004; 101(3): 737 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
K. Kaneko, K. Uchida, T. Kobayashi, K. Miura, K. Tanokura, K. Hoshino, I. Kato, M. Onoue, and T. Yokokura
Sex-Dependent Toxicity of a Novel Acyl-CoA:Cholesterol Acyltransferase Inhibitor, YIC-C8-434, in Relation to Sex-Specific Forms of Cytochrome P450 in Rats
Toxicol. Sci., December 1, 2001; 64(2): 259 - 268.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Yagyu, T. Kitamine, J.-i. Osuga, R.-i. Tozawa, Z. Chen, Y. Kaji, T. Oka, S. Perrey, Y. Tamura, K. Ohashi, et al.
Absence of ACAT-1 Attenuates Atherosclerosis but Causes Dry Eye and Cutaneous Xanthomatosis in Mice with Congenital Hyperlipidemia
J. Biol. Chem., July 7, 2000; 275(28): 21324 - 21330.
[Abstract] [Full Text] [PDF]